|
Cetuximab plus platinum-based chemotherapy in patients with malignant pleural mesothelioma: A single arm phase II trial. |
|
|
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Chiesi; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst) |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst) |
Travel, Accommodations, Expenses - Roche |